1 / 9

Ombitasvir- Paritaprevir - Ritonavir and Dasabuvir +/- RBV in GT1 PEARL-III and PEARL-IV

Phase 3. Treatment Naïve. Ombitasvir- Paritaprevir - Ritonavir and Dasabuvir +/- RBV in GT1 PEARL-III and PEARL-IV. Ferenci P, et al. N Engl J Med. 2014;370:1983-92. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1 PEARL -III and PEARL-IV: Study Design.

marcel
Download Presentation

Ombitasvir- Paritaprevir - Ritonavir and Dasabuvir +/- RBV in GT1 PEARL-III and PEARL-IV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentNaïve Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV Ferenci P, et al. N Engl J Med. 2014;370:1983-92.

  2. Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Study Design Source: FerenciP, et al. N Engl J Med. 2014;370:1983-92.

  3. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Study Regimens 0 12 24 Week HCV Genotype 1a SVR12 n = 100 3D + Ribavirin SVR12 n = 205 3D + Placebo HCV Genotype 1b SVR12 n = 210 3D+ Ribavirin SVR12 n = 209 3D + Placebo 3D =Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir Drug Dosing3D = Ombitasvir-Paritaprevir-Ritonavir (25/150/100 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Ferenci P, et al. N Engl J Med. 2014;370:1983-92.

  4. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Baseline Characteristics Source: Ferenci P, et al. N Engl J Med. 2014;370:1983-92.

  5. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Results 97/100 185/205 209/210 207/209 Genotype 1a Genotype 1b 3D = Ombitasvir-Paritaprevir-Ritonavirand DasabuvirRBV = Ribavirin Source: Ferenci P, et al. N Engl J Med. 2014;370:1983-92.

  6. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Adverse Events Source: Ferenci P, et al. N Engl J Med. 2014;370:1983-92.

  7. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Adverse Events Source: Ferenci P, et al. N Engl J Med. 2014;370:1983-92.

  8. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1PEARL-III and PEARL-IV: Conclusions Note: ABT-450/r = Paritaprevir-Ritonavir Source: FerenciP, et al. N Engl J Med. 2014;370:1983-92.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related